\
&
Contact us
\
&
Contact us
Published on | 1 year ago
Programmes Digital, Industry & Space Digital Europe AI ContinentThe European Commission has published a document to respond to Frequently Asked Questions (FAQs) on the Data Act.
The Data Act, which will become applicable on 12 September 2025, establishes a horizontal set of rules on data access and use that aims to protect fundamental rights and to deliver wide-ranging benefits for the European economy and society. It increases data availability – particularly industrial data – and encourages data-driven innovation while ensuring fairness in the allocation of data value among all actors in the data economy.
It will contribute to the establishment of a single market for data, together with the Data Governance Act, which aims to increase trust in voluntary data-sharing mechanisms.
As applicants to data-related call topics are expected to be aware of relevant EU policies and legislation, these FAQs can provide a useful overview on the Data Act.
We offer news and event updates, covering all domains and topics of Horizon Europe, Digital Europe & EDF (and occasionally, for ongoing projects, Horizon 2020).
Stay informed about what matters to you.
By signing up, you can opt in for e-mail notifications and get access to
a personalised dashboard that groups all news updates and event announcements in your domain(s).
Only for stakeholders located in Flanders
The Horizon2020 project BEAT-AF brings together 9 European renowned clinical centres in France, Belgium, Czechia, Germany and Austria. Together, the consortium strives to revolutionize Atrial Fibrillation (AF) treatment through catheter ablation and contribute to decrease the huge burden of AF in Europe. The BEAT-AF project kicked off in 2021 and will run until 2026. The department of electrophysiology of the AZ Sint-Jan Hospital in Bruges is partner in the project and has so far contributed to the pre-clinical development, the first in man studies and first registries of the revolutionary AF treatment put forward by the consortium. The first pilot studies show that the treatment is safe, effective and efficient.
